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for Preventing Chemotherapy-Induced
Left Ventricular Systolic Dysfunction in
Patients With Malignant HemopathiesWe thank Dr. Golwala and Dr. Spallarossa and colleagues for their
interest in our study. Both ask about the lack of association found
in our study (1) between troponin elevation and beneﬁt from
pharmacological intervention. The value of troponins to predict left
ventricular systolic dysfunction (LVSD) has been reported with
anthracyclines but not with other drugs (2). However, we do
not believe that our results are contradictory to those of Cardinale
et al. (3); differences in the patient population, intensity and type
of chemotherapy, and protocol design of both studies may account
for their different results. Cardinale et al. included only patients
with positive troponin levels 1 month after treatment, selecting
a population at a particularly high risk for developing a marked
drop in left ventricular ejection fraction (LVEF) (43% in their
control group), whereas we enrolled all incoming patients. In our
study, 10 of the 11 patients with positive troponin levels had acute
leukemia, a subgroup of patients that received anthracyclines and
a more intense chemotherapy regimen and in whom we observed
a marked effect of the intervention. Large randomized trials are
needed to determine whether a strategy of primordial prevention
with cardioprotective drugs to all patients is more effective than
a troponin-directed strategy.
Dr. Golwala questions the value of the results of the intervention
on a secondary endpoint of the study, the combined endpoint of
mortality, heart failure, and signiﬁcant LVSD, due to the potential
confounding factor of sepsis. As discussed in the paper, because
two-thirds of all deaths were related to sepsis, it is difﬁcult to
elucidate whether enalapril and carvedilol could have inﬂuenced
mortality. However, survivors of sepsis had a lower LVEF, and this
condition is a well-known determinant of mortality. Other factorsshould be considered because 8 of the 13 patients who survived
a septic episode had acute leukemia, a subgroup of patients with
a marked beneﬁt from the intervention. In addition, the effects on
LVEF were observed, not only among the patients who survived
a septic episode, but also in the other 66 patients, especially in
patients with acute leukemia in which a 5  5.7% intergroup
absolute difference was observed. Finally, a positive trend for the
intervention was also observed in the number of patients with heart
failure or a drop of 10% in LVEF, although the incidence was too
low to preclude deﬁnite conclusions.
We agree with Dr. Spallarossa and colleagues that the antioxi-
dant effect of carvedilol may play an important role in its car-
dioprotective effect (as do their demonstrated antiapoptotic and
pleiotropic effects) and on the importance to correctly treat
hypertensive patients treated with chemotherapy. Because, by
protocol, angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, and beta-blockers were not allowed in our study,
the 8 hypertensive patients of the control group were treated with
amlodipine; at 6 months follow-up, their mean systolic pressure
was 122  13 mm Hg.
Finally, we understand the safety concern of Dr. Spallarossa et al.
about the rapid initial up-titration of enalapril and carvedilol in
these high-risk patients. This concern was indeed the reason for not
performing a double-blind study with placebo. The protocol used
was safe because all patients had normal LVEF and were treated in-
hospital during frontline therapy under close supervision for a mean
of 1 month, and in no cases did the study treatment prevent the
patients from receiving the optimal chemotherapy regimen. The
tight cooperation we had between hematologists and cardiologists
was certainly the key.*Xavier Bosch, MD
Marta Sitges, MD
Montserrat Rovira, MD
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